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AIM of the WORK: This is a prospective study to determine the prevalence, the clinical and the pathological features of gastric autoimmunity in patients recently diagnosed with Hashimoto’s Thyroiditis. A second objective is to determine clinical and/or biological significant predictive factors of gastric autoimmunity to improve diagnosis in these patients. 

METHODS: A total of 360 consecutive patients with Hashimoto’s Thyroiditis were studied in our clinic from 2008 to 2010. These patients had no other clinical features of autoimmunity (vitiligo, Addison, candidiasis, etc). Patients underwent TSH, FT4, FT3, ATPO, ATG, parietal cell autoantibodies (PCA), intrinsic factor antibodies (IFA), gastrin, vitamin B12 determinations and thyroid ultrasounds. Patients with PCA and/or IFA were invited to have a gastric endoscopy and biopsies for histology and immunohistochemical studies.  To determine predictive factor of autoimmunity they were compared to a control group of 30 patients matched for sex and age (these patients had Hashimoto’s Thyroiditis but serologic gastric autoimmunity was ruled out). 

MAIN RESULTS: Patients with Hashimoto’s Thyroiditis and gastric autoimmunity had a mean age of 50±17 years (40F/8M) at inclusion. Mean TSH was 9,6 ±42 mUI/ml (0.5-4). Mean thyroid volume was 9±7 ml.  Parietal cell autoantibodies were present in 13% (48/360). Intrinsic factor autoantibodies were found in 27% (6/22). Hypergastrinemia (>120 pg/ml) was present in 37,5 % (18/48) of patients with a mean of 186±572pg/ml. No patient had anemia, whereas only four patients had  macrocytosis and 6 patients had microcytosis. Vitamine B12 was less than  200 pg/ml in 19% (9/48) of patients.

A total of 56% (27/48) with PCA and no gastric symptoms underwent a gastroscopy. Gastroscopy revealed mucosal abnormalities in 74% (20/27). Gastric and duodenal biopsies shown in 74% (20/27)  histological signs of lymphocitosis infiltration. Another 37% (10/27) had signs of metaplasia and ECC hyperplasia, and only 26% (7/27) of patients had signs of mucosal atrophy. Interestingly, H Pilori infection was found in 22% (6/27) of patients: follow-up in some of these patients showed PCA negativization after H Pilori eradication. No gastric carcinoid was found in this prospective series.

CONCLUSIONS: The thyrogastric syndrome should be differentiated of classical forms of autoimmune  polyendocrine syndrome (type I, II or III), that  are uncommon. H Pilori can mimick gastric autoimmunity in Hashimoto Thyroiditis but this is reversible after eradication. The high prevalence of autoimmune gastritis and vitamin B12 deficiency in this series provide a strong rationale for an early serologic screening and gastroscopic diagnosis in patients with Hashimoto’s thyroiditis. 

